NEW YORK (GenomeWeb) – Next-generation sequencing-based clinical diagnostics firm Blueprint Genetics today announced it has raised $3.9 million to fund its international expansion.

It is unclear if the $3.9 million figure is the amount the Finnish firm raised in the most recent financing round or if it is the total amount raised since its founding. On deadlinie, the company did not respond to a request for clarification.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.